핵산 분리 및 정제 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품 유형별, 용도별, 수법별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Nucleic Acid Isolation And Purification Market Growth & Trends:

The global nucleic acid isolation and purification market size is estimated to reach USD 9.77 billion by 2030, registering a CAGR of 9.61% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the increasing number of cancer cases, chronic diseases prevalence, and rising public-private funding for biotechnology and life sciences research. In addition, advancements in automation and technology, and growing demand for genetically modified crops and organisms also contribute to the market growth. For instance, in December 2023, HiMedia Labs elaborated the significance and efficacy of magnetic bead-based systems in nucleic acid extraction and applying nucleic acid isolation and purification in various end-use industries.

The number of precision medicines developed for treating multiple diseases, such as diabetes, cancer, rheumatoid arthritis, neurological diseases, and autoimmune diseases. This market is introduced with the various new approaches, aiding the manipulation of genes. For instance, the companies are investing in a platform that delivers nucleic acids, such as small interfering RNAs (siRNAs), to address gene overexpression and mutations in conditions such as cancer, genetic disorders, and autoimmune diseases. Researchers are constantly trying to find effective therapeutics for patients. The upcoming new precision therapies may hold the key to treat incurable diseases. The use of nucleic acids and nucleic acid isolation & purification products and technologies are, therefore, very crucial for developing precision medicines.

The research and development (R&D) efforts in human genomics conducted by pharmaceutical and biotechnology companies have significantly transformed disease diagnosis and treatment development. The nucleic acid isolation and purification kits and instruments market is crucial in new drug discovery, target identification, and testing, particularly in genome editing. Substantial investments in R&D and drug discovery projects drive the competitive rivalry among companies in this space. The increasing adoption of emerging technologies for therapy development is expected to further drive market growth, with nucleic acid isolation and purification serving as a key step in manufacturing drugs and therapies through recombinant genetics. Key factors contributing to growth include the widespread use of CRISPR technology for identifying and validating therapeutics, creating improved animal testing models, and reducing the cost of research and development for drug discovery in preclinical trials.

Nucleic Acid Isolation And Purification Market Report Highlights:

• Based on product, kits & reagents dominated the market with a largest revenue share in 2024, owing to the growing demand for kits for DNA/RNA extraction and purification.
• The instruments segment is expected to grow at a significant CAGR over the forecast period.
• Based on type, the DNA isolation and purification segment held the largest revenue share in 2024, owing to its variety of applications in the molecular biology field.
• The RNA isolation and purification segment is anticipated to witness a significant growth over the forecast period. The growth is attributed to its applications in gene expression profiling, sequencing, and clinical diagnostics.
• Based on application, the diagnostic segment led the market in 2024, owing to the rising application of DNA and RNA isolation for identifying pathogens in routine sample processing.
• The drug discovery & development segment is expected to grow at the significant CAGR over the forecast period, due to the increasing number of chronic diseases and other disorders.
• Based on method, the magnetic beads segment led the market in 2024. This can be attributed to its high efficacy and applications in a variety of fields.
• The column-based segment is expected to register a significant growth rate during the forecast period.
• Based on the end-use, the hospitals and diagnostics centers segment held the largest revenue share in 2024. The growth is due to the increased use of nucleic acid in a broad range of healthcare segments.
• The pharmaceutical and biotechnology companies segment is expected to register the fastest CAGR during the projected period.
• Based on region, North America dominated the global NAIP market, owing to factors such as leveraged government support, a favorable regulatory framework, and consistent R&D efforts.
• Asia Pacific is expected to grow at the fastest CAGR during the forecast period, due to several business initiatives undertaking in countries such as China, Japan, and India.
• In December 2023, Thermo Fisher Scientific Inc. launched an automatic nucleic acid purification instrument, Thermo Scientific KingFisher Apex Dx, and Applied Biosystems MagMAX Dx Pathogen/Viral NA Isolation Kit to isolate and purify bacterial and viral pathogens from biological samples.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. Method
  • 1.2.5. End use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Nucleic Acid Isolation And Purification Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence of cancer, genetic disorders, and infectious diseases
    • 3.2.1.2. Increase in public-private funding for biotechnology and life science research
    • 3.2.1.3. Advancements in automation
    • 3.2.1.4. Growth in NGS technologies
    • 3.2.1.5. Growing demand for genetically modified crops and organisms
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Expensive instruments and consequent low penetration in emerging countries
    • 3.2.2.2. Challenges related to the use of big data and bioinformatics
• 3.3. Industry Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Analysis

Chapter 4. Product Business Analysis

• 4.1. Nucleic Acid Isolation and Purification Market: Product Movement Analysis
• 4.2. Kits & Reagents
  • 4.2.1. Kits & reagents market estimates and forecasts 2018 - 2030 (USD Million)
• 4.3. Instruments
  • 4.3.1. Instruments market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.3.2. Manual
    • 4.3.2.1. Manual market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.3.3. Automatic
    • 4.3.3.1. Automatic market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

• 5.1. Nucleic Acid Isolation and Purification Market: Type Movement Analysis
• 5.2. DNA Isolation & Purification
  • 5.2.1. DNA isolation & purification market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.2.2. Genomic DNA Isolation & Purification
    • 5.2.2.1. Genomic DNA isolation & purification market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.2.3. Plasmid DNA Isolation & Purification
    • 5.2.3.1. Plasmid DNA isolation & purification market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.2.4. Viral DNA Isolation & Purification
    • 5.2.4.1. Viral DNA isolation & purification market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.2.5. Other
    • 5.2.5.1. Other market estimates and forecasts 2018 - 2030 (USD Million)
• 5.3. RNA Isolation & Purification
  • 5.3.1. RNA isolation & purification market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.3.2. miRNA Isolation & Purification
    • 5.3.2.1. miRNA isolation & purification market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.3.3. mRNA Isolation & Purification
    • 5.3.3.1. mRNA isolation & purification market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.3.4. Total RNA Isolation & Purification
    • 5.3.4.1. Total RNA isolation & purification market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.3.5. Other
    • 5.3.5.1. Other market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Nucleic Acid Isolation and Purification Market: Application Movement Analysis
• 6.2. Precision Medicine
  • 6.2.1. Precision medicine market estimates and forecasts 2018 - 2030 (USD Million)
• 6.3. Diagnostics
  • 6.3.1. Diagnostics market estimates and forecasts 2018 - 2030 (USD Million)
• 6.4. Drug Discovery & Development
  • 6.4.1. Drug discovery & development market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Agriculture and Animal Research
  • 6.5.1. Agriculture and animal research market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Other Applications
  • 6.6.1. Other applications market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Method Business Analysis

• 7.1. Nucleic Acid Isolation and Purification Market: Method Movement Analysis
• 7.2. Column Based
  • 7.2.1. Column based medicine market estimates and forecasts 2018 - 2030 (USD Million)
• 7.3. Magnetic Beads
  • 7.3.1. Magnetic beads market estimates and forecasts 2018 - 2030 (USD Million)
• 7.4. Reagent Based
  • 7.4.1. Reagent based market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. End Use Business Analysis

• 8.1. Nucleic Acid Isolation and Purification Market: End Use Movement Analysis
• 8.2. Academic Research Institutes
  • 8.2.1. Academic research institutes market estimates and forecasts 2018 - 2030 (USD Million)
• 8.3. Pharmaceutical and Biotechnology Companies
  • 8.3.1. Pharmaceutical and biotechnology companies market estimates and forecasts 2018 - 2030 (USD Million)
• 8.4. Contract Research Organizations
  • 8.4.1. Contract research organizations market estimates and forecasts 2018 - 2030 (USD Million)
• 8.5. Hospitals and Diagnostic Centers
  • 8.5.1. Hospitals and diagnostic centers market estimates and forecasts 2018 - 2030 (USD Million)
• 8.6. Other End-use
  • 8.6.1. Other end-use market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. 4.1. Nucleic Acid Isolation and Purification Market: Regional Outlook
• 9.2. North America
  • 9.2.1. North America market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key country dynamics
    • 9.2.2.2. Competitive scenario
    • 9.2.2.3. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key country dynamics
    • 9.2.3.2. Competitive scenario
    • 9.2.3.3. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key country dynamics
    • 9.2.4.2. Competitive scenario
    • 9.2.4.3. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Competitive scenario
    • 9.3.2.3. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Competitive scenario
    • 9.3.3.3. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Competitive scenario
    • 9.3.4.3. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key country dynamics
    • 9.3.5.2. Competitive scenario
    • 9.3.5.3. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key country dynamics
    • 9.3.6.2. Competitive scenario
    • 9.3.6.3. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.7. Norway
    • 9.3.7.1. Key country dynamics
    • 9.3.7.2. Competitive scenario
    • 9.3.7.3. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key country dynamics
    • 9.3.8.2. Competitive scenario
    • 9.3.8.3. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.9. Denmark
    • 9.3.9.1. Key country dynamics
    • 9.3.9.2. Competitive scenario
    • 9.3.9.3. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Competitive scenario
    • 9.4.2.3. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Competitive scenario
    • 9.4.3.3. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Competitive scenario
    • 9.4.4.3. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Competitive scenario
    • 9.4.5.3. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.6. South Korea
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Competitive scenario
    • 9.4.6.3. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Competitive scenario
    • 9.4.7.3. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Competitive scenario
    • 9.5.2.3. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Competitive scenario
    • 9.5.3.3. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 9.6. MEA
  • 9.6.1. MEA market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Competitive scenario
    • 9.6.2.3. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Competitive scenario
    • 9.6.3.3. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Competitive scenario
    • 9.6.4.3. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Competitive scenario
    • 9.6.5.3. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. QIAGEN
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Thermo Fisher Scientific, Inc.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Illumina, Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Danaher
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. F. Hoffmann-La Roche Ltd
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Merck KGaA
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Agilent Technologies
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Bio-Rad Laboratories, Inc.
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Takara Bio Inc.
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Promega Corporation
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives